Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2008-06-03
2008-06-03
Carr, Deborah D (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S561000
Reexamination Certificate
active
07381747
ABSTRACT:
This invention relates to a method of treating a disorder selected from OCD, agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, PTSD, restless legs syndrome, premenstrual dysphoric disorder, hot flashes, and fibromyalgia by administering a compound of the formula 1or a pharmaceutically acceptable salt thereof, wherein:R1is hydrogen, straight or branched alkyl of from 1 to 6 carbon atoms or phenyl; andR2is straight or branched alkyl of from 4 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl OH, -alkylphenyl, -alkylphenoxy, or -substituted phenyl. The invention also relates to a method of treating the above disorders by administering the compound (3S,5R)-3-Aminomethyl-5-methyl-octanoic acid.
REFERENCES:
patent: 4024175 (1977-05-01), Satzinger et al.
patent: 4087544 (1978-05-01), Satzinger et al.
patent: 5670539 (1997-09-01), Richardson
patent: 5919823 (1999-07-01), Richardson
patent: 6001876 (1999-12-01), Singh et al.
patent: 6117908 (2000-09-01), Andrews et al.
patent: 6127418 (2000-10-01), Bueno et al.
patent: 6248363 (2001-06-01), Patel et al.
patent: 6306910 (2001-10-01), Magnus et al.
patent: 6309663 (2001-10-01), Patel et al.
patent: 6310098 (2001-10-01), Guttuso, Jr.
patent: 6372792 (2002-04-01), Chouinard
patent: 6642398 (2003-11-01), Belliotti et al.
patent: 2002/0035057 (2002-03-01), Richter et al.
patent: 2002/0037926 (2002-03-01), Lan
patent: 2002/0072538 (2002-06-01), Chenard et al.
patent: 2002/0099013 (2002-07-01), Piccariello et al.
patent: 2002/0099092 (2002-07-01), Blakemore et al.
patent: 2002/0165246 (2002-11-01), Holman
patent: 2003/0144214 (2003-07-01), Blakemore et al.
patent: 198 02 327 (1999-07-01), None
patent: 0641330 (2001-10-01), None
patent: 98/17627 (1998-04-01), None
patent: WO 98/17627 (1998-04-01), None
patent: WO 99/21824 (1999-05-01), None
patent: WO 00/76958 (2000-12-01), None
patent: WO 01/13904 (2001-03-01), None
patent: WO 01/28978 (2001-04-01), None
patent: WO 01/45714 (2001-06-01), None
patent: WO 01/90052 (2001-11-01), None
patent: WO 02/34237 (2002-05-01), None
patent: WO 03/061656 (2003-07-01), None
M.V. Ameringen, et al., “Drugs in Development for Social Anxiety Disorder: More to Social Anxiety Than Meets the SSRI”; Expert Opinion on Investigational Drugs, 2000; pp. 2215-2231; vol. 9- No. 10; Ashley Pub. Ltd., London, GB.
A. Barkhuizen, “Rational and Targeted Pharmacologic Treatment of Fibromyalgia”, Rheumatic Disease Clinic of North America; 2002; pp. 261-290; 28.
R. M. Bennett, “The Rational management of Fibromyalgia Patients”;Rheumatic Disease Clinic of North America; 2002; pp. 181-199; 28.
D. Buskila, “Fibromyalgia, Chronic Fatigue Syndrome and Myofacial Pain Syndrome”; Current Opinions in Rheumatology; 2001; pp. 117-127; 13.
B.L. Ehrenberg, et al., “Open-Label Trial of Gabapentin for Periodic Limb Movement Disorder of Sleep”; Neurology; Mar. 1997; pp. A278-A279, vol. 48.
E.K. Guymer, et al., “An Approach to Managing Fibromyalgia”; Medicine Today; 2002; pp. 58-59; vol. 3, No. 12.
L.J. Leventhal, “Management of Fibromyalgia”; Ann Intern Med.; 1999; pp. 850-859; 131.
L.T. Meltzer, et al., “Pregabalin Enhances Non-Rapid Eye Movement Sleep and EEG Slow-Wave Activity in Rats”; Society for Neuroscience Abstacts; 2001; p. 2245; vol 27, No. 2.
I. Selak; “Pregabalin (Pfizer);” Current Opinion in Investigational Drugs; 2001; pp. 828-834; vol. 2, No. 6.
F. Wolfe, et al., “The American Colley of Rheumatology 1990 Criteria for the Classification of Fibromyalgia: Report of the Multicenter Criteria Committee”; Arthritis Rheum., 1990; pp. 160-172; 33.
M.B. Yunus, “A Comprehensive Medical Evaluation of Patients with Fibromyalgia Syndrome”; Rheumatic Disease Clinic of North America; 2002; pp. 201-217; 28.
D. Garcia-Borreguero, et al., “Treatment of Restless Legs Syndrome with Gabapentin—A Double Blind, Cross-Over Study”; Neurology, Nov. 2002; pp. 1573-1579; 59.
Heidi D. Nelson, et al., “Nonhormonal Therapies for Menopausal Hot Flashes-Systematic Review and Meta-analysis”; Journal of American Medical Association; May 3, 2006, pp. 2057-2071; vol. 295, No. 17.
Albucher, et al., “Psychopharmacological Treatment in PTSD: A Critical Review,” Journal of Psychiatric Research, 36, pp. 355-367, 2002.
Fava, et al., “Sequential Treatment of Mood and Anxiety Disorders,” Journal of Psychiatry, 66, pp. 1392-1400, 2005.
Keller, “Citralopram Therapy for Depression: A Review of 10 Years of European Experience and Data From U.S. Clinical Trials,” Journal of Clinical Psychiatry, 61, pp. 896-908, 2000.
Moroz, “High-Potency Benzodiazepines: Recent Clinical Results,” Journal of Clinical Psychiatry, 65, Suppl. 5, pp. 13-18, 2004.
Stein, “Medication Treatments For Panic Disorder and Social Phobia,” Depression and Anxiety, 7, pp. 134-138, 1998.
Soravia, et al., “Glucocorticoids Reduce Phobic Fear in Humans,” PNAS, 103, pp. 5585-5590, 2006.
Bandelow, et al., “The Use of the Panic and Agoraphobia Scale (P&A) In A controlled Clinical Trial,” Pharmacopsychiatry, 33, pp. 174-181, 2000.
Dooley David James
Taylor, Jr. Charles Price
Thorpe Andrew John
Wustrow David Juergen
Benson Gregg C.
Carr Deborah D
Goddard Carl J.
Warner-Lambert Company LLC
LandOfFree
Alpha 2 delta ligands for post-traumatic stress disorder does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha 2 delta ligands for post-traumatic stress disorder, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha 2 delta ligands for post-traumatic stress disorder will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2800926